AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

3,334.00GBp
12:08pm EDT
Price Change (% chg)

-1.00p (-0.03%)
Prev Close
3,335.00p
Open
3,369.50p
Day's High
3,379.50p
Day's Low
3,284.00p
Volume
2,247,700
Avg. Vol
2,054,692
52-wk High
3,544.50p
52-wk Low
2,786.00p

AZN.L

Chart for AZN.L

About

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes treatments... (more)

Overall

Beta: 0.41
Market Cap (Mil.): £41,844.39
Shares Outstanding (Mil.): 1,252.22
Dividend: 122.26
Yield (%): 5.40

Financials

  AZN.L Industry Sector
P/E (TTM): 11.25 37.93 37.76
EPS (TTM): 2.97 -- --
ROI: 15.60 19.48 18.76
ROE: 25.88 20.17 19.59
Search Stocks

WRAPUP 1-Drugmakers fear short-term "turmoil" as China probes widen

* AstraZeneca CEO sees short-term disruption, price pressure

8:28am EDT

AstraZeneca unit looking at biosimilars, no comment on Celltrion

LONDON, Aug 1 - AstraZeneca is looking at ways to leverage its capacity to make biotech drugs within its MedImmune unit, including a possible move into so-called biosimilars, its chief executive said on Thursday.

5:35am EDT

AstraZeneca warns of higher costs as drug sales slide

LONDON - British drugmaker AstraZeneca warned on Thursday of higher costs in 2013 as it invests through a slump in sales caused by a wave of patent expiries on key medicines.

4:47am EDT

UPDATE 2-AstraZeneca warns of higher costs as drug sales slide

LONDON, Aug 1 - British drugmaker AstraZeneca warned on Thursday of higher costs in 2013 as it invests through a slump in sales caused by a wave of patent expiries on key medicines.

4:41am EDT

AstraZeneca drug sales fall on patent expiries in second quarter

LONDON, Aug 1 - AstraZeneca sales fell by a slightly more -than-expected 6 percent in the second quarter, hurt by loss of patent protection on key drugs, while earnings tumbled nearly a quarter due to a higher tax rate.

2:19am EDT

UPDATE 1-AstraZeneca in $815 mln 'high altitude' anaemia pill deal

LONDON, July 31 - AstraZeneca took another step to bolster its new drug pipeline on Wednesday by striking a deal with U.S. biotech firm FibroGen potentially worth more than $815 million for rights to an experimental anaemia drug.

31 Jul 2013

BRIEF-Source Bioscience provides update on funding for Vindon Healthcare buy

July 24 - Source Bioscience plc : * Update re funding for possible offer * Conditionally raised GBP 9.5 million firm with new and existing institutional

24 Jul 2013

UPDATE 3-U.S. citizen detained as China pharma probe spreads

* 39 hospital staff to be punished for taking bribes-Xinhua

23 Jul 2013

Array asthma drug meets main goal in mid-stage study

- Array Biopharma Inc said one of its drugs met the main goal of improving lung function in a mid-stage study among patients with mild to moderate persistent allergic asthma.

23 Jul 2013

Two more AstraZeneca employees questioned in China

LONDON - Chinese police have questioned two more AstraZeneca employees in Shanghai, after a sales representative was taken away for questioning earlier, the British drugmaker said on Tuesday.

23 Jul 2013

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Wright Reports
$472.00
Provider: Plunkett Research, Ltd.
$99.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks